169 related articles for article (PubMed ID: 29085443)
1. The involvement of E6, p53, p16, MDM2 and Gal-3 in the clinical outcome of patients with cervical cancer.
Stiasny A; Freier CP; Kuhn C; Schulze S; Mayr D; Alexiou C; Janko C; Wiest I; Dannecker C; Jeschke U; Kost BP
Oncol Lett; 2017 Oct; 14(4):4467-4476. PubMed ID: 29085443
[TBL] [Abstract][Full Text] [Related]
2. The roles of E6-AP and MDM2 in p53 regulation in human papillomavirus-positive cervical cancer cells.
Traidej M; Chen L; Yu D; Agrawal S; Chen J
Antisense Nucleic Acid Drug Dev; 2000 Feb; 10(1):17-27. PubMed ID: 10726657
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical Evaluation of E6/E7 HPV Oncoproteins Staining in Cervical Cancer.
Stiasny A; Kuhn C; Mayr D; Alexiou C; Janko C; Wiest I; Jeschke U; Kost B
Anticancer Res; 2016 Jun; 36(6):3195-8. PubMed ID: 27272848
[TBL] [Abstract][Full Text] [Related]
4. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas.
Ikenberg H; Matthay K; Schmitt B; Bauknecht T; Kiechle-Schwarz M; Göppinger A; Pfleiderer A
Cancer; 1995 Jul; 76(1):57-66. PubMed ID: 8630877
[TBL] [Abstract][Full Text] [Related]
5. The presence of human papillomavirus-16/-18 E6, p53, and Bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer.
Pillai MR; Halabi S; McKalip A; Jayaprakash PG; Rajalekshmi TN; Nair MK; Herman B
Cancer Epidemiol Biomarkers Prev; 1996 May; 5(5):329-35. PubMed ID: 9162297
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical Evaluation of the Role of p53 Mutation in Cervical Cancer: Ser-20 p53-Mutant Correlates with Better Prognosis.
Freier CP; Stiasny A; Kuhn C; Mayr D; Alexiou C; Janko C; Wiest I; Jeschke U; Kost B
Anticancer Res; 2016 Jun; 36(6):3131-7. PubMed ID: 27272838
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of p16 and p14ARF is associated with human papillomavirus infection in cervical squamous cell carcinoma and dysplasia.
Sano T; Masuda N; Oyama T; Nakajima T
Pathol Int; 2002; 52(5-6):375-83. PubMed ID: 12100520
[TBL] [Abstract][Full Text] [Related]
8. Differences in the ubiquitination of p53 by Mdm2 and the HPV protein E6.
Camus S; Higgins M; Lane DP; Lain S
FEBS Lett; 2003 Feb; 536(1-3):220-4. PubMed ID: 12586367
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation.
Cheng YW; Wu MF; Wang J; Yeh KT; Goan YG; Chiou HL; Chen CY; Lee H
Cancer Res; 2007 Nov; 67(22):10686-93. PubMed ID: 18006810
[TBL] [Abstract][Full Text] [Related]
10. Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways.
Goodwin EC; DiMaio D
Proc Natl Acad Sci U S A; 2000 Nov; 97(23):12513-8. PubMed ID: 11070078
[TBL] [Abstract][Full Text] [Related]
11. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells.
Ristriani T; Fournane S; Orfanoudakis G; Travé G; Masson M
Oncogene; 2009 Feb; 28(5):762-72. PubMed ID: 19015633
[TBL] [Abstract][Full Text] [Related]
12. DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer.
Wu DW; Lee MC; Wang J; Chen CY; Cheng YW; Lee H
Oncogene; 2014 Mar; 33(12):1515-26. PubMed ID: 23584477
[TBL] [Abstract][Full Text] [Related]
13. HPV-16 E6 and E7 oncogene expression is downregulated as a result of Mdm2 knockdown.
Diaz D; Santander MA; Chavez JA
Int J Oncol; 2012 Jul; 41(1):141-6. PubMed ID: 22504553
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical expression of mdm2 and p21WAF1 in invasive cervical cancer: correlation with p53 protein and high risk HPV infection.
Troncone G; Martinez JC; Palombini L; De Rosa G; Mugica C; Rodriguez JA; Zeppa P; Di Vizio D; Lucariello A; Piris MA
J Clin Pathol; 1998 Oct; 51(10):754-60. PubMed ID: 10023338
[TBL] [Abstract][Full Text] [Related]
15. Quercetin induces G2 phase arrest and apoptosis with the activation of p53 in an E6 expression‑independent manner in HPV‑positive human cervical cancer‑derived cells.
Clemente-Soto AF; Salas-Vidal E; Milan-Pacheco C; Sánchez-Carranza JN; Peralta-Zaragoza O; González-Maya L
Mol Med Rep; 2019 Mar; 19(3):2097-2106. PubMed ID: 30664221
[TBL] [Abstract][Full Text] [Related]
16. Characterization of humoral immune responses against p16, p53, HPV16 E6 and HPV16 E7 in patients with HPV-associated cancers.
Reuschenbach M; Waterboer T; Wallin KL; Einenkel J; Dillner J; Hamsikova E; Eschenbach D; Zimmer H; Heilig B; Kopitz J; Pawlita M; Doeberitz Mv; Wentzensen N
Int J Cancer; 2008 Dec; 123(11):2626-31. PubMed ID: 18785210
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic and predictive value of koilocytosis, expression of e6 hpv types 16/18, p16ink4a, p53 in locally advanced squamous cell carcinomas of oral cavity and oropharynx, associated with human papillomavirus].
Riaboshapka AN
Georgian Med News; 2014 Nov; (236):48-55. PubMed ID: 25541826
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation.
Alarcón R; Koumenis C; Geyer RK; Maki CG; Giaccia AJ
Cancer Res; 1999 Dec; 59(24):6046-51. PubMed ID: 10626788
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical co-expression of human papillomavirus type 16/18 transforming (E6) oncoprotein and p53 tumour suppressor gene proteins in oesophageal cancer.
Agarwal SK; Chatterji A; Bhambhani S; Sharma BK
Indian J Exp Biol; 1998 Jun; 36(6):559-63. PubMed ID: 9731468
[TBL] [Abstract][Full Text] [Related]
20. Relationship between HPV16/18 E6 and 53, 21WAF1, MDM2, Ki67 and cyclin D1 expression in esophageal squamous cell carcinoma: comparative study by using tissue microarray technology.
Qi ZL; Huo X; Xu XJ; Zhang B; Du MG; Yang HW; Zheng LK; Li J; Shen ZY
Exp Oncol; 2006 Sep; 28(3):235-40. PubMed ID: 17080019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
